BioStock

Prenumeration

Spago’s phase I/IIa cancer study on track for 2025 completion

2025-06-09 10:27:00

Spago Nanomedical has received approval to continue its phase I/IIa Tumorad-01 study with the cancer drug candidate 177Lu-SN201 at the highest current dose level, following a positive safety review. The study progresses with patient recruitment in Australia, aiming for completion of the initial phase I in 2025. We spoke with the CEO Mats Hansen for a comment.

Read the full interview at biostock.se:

https://biostock.se/en/2025/06/spagos-phase-i-iia-cancer-study-on-track-for-2025-completion/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden